AVIR — Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash and cash equivalents totaled $301.8 million as of December 31, 2025, providing a strong financial position to support ongoing clinical programs.
• The company returned $25 million to shareholders through a share repurchase program in 2025.
• R&D expenses increased in 2025 compared to 2024, primarily due to external spending on the HCV Phase III clinical development, while G&A expenses decreased due to lower stock-based compensation.

2. Strategic Updates and Business Highlights:

• Atea is advancing its global Phase III program for bemnifosbuvir and ruzasvir for HCV treatment, with top-line results expected midyear for the C-BEYOND trial and by year-end for the C-FORWARD trial.
• The company is expanding its antiviral pipeline to include AT-587, targeting chronic hepatitis E (HEV) infections, with plans to initiate a first-in-human study by mid-2026.
• Atea's regimen for HCV is positioned as a potential best-in-class treatment, with a focus on a short treatment duration, low risk of drug-drug interactions, and convenience.

3. Forward Guidance and Outlook:

• Atea anticipates a cash runway extending through 2027, allowing for continued investment in clinical trials and preparations for product launches.
• The company expects to achieve profitability shortly after the commercial launch of its HCV regimen, supported by a focused specialty sales force of approximately 75 people.

4. Challenges and Points of Concern:

• The market for HCV treatments is competitive, with legacy regimens facing pricing pressures and a highly concentrated prescriber base.
• Despite the promising data, the company must navigate the complexities of market acceptance and payer dynamics, particularly as they relate to pricing and formulary inclusion.
• The ongoing high rate of new HCV infections in the U.S. presents both a challenge and an opportunity, as treatment rates currently lag behind infection rates.

5. Notable Q&A Insights:

• Atea's management expressed confidence in meeting enrollment targets for both C-BEYOND and C-FORWARD trials, indicating no issues with cirrhotic patient enrollment.
• The commercial landscape is evolving, with Atea's regimen seen as favorable by payers and prescribers, who are interested in its profile and potential for inclusion in formularies.
• The company highlighted the significance of treatment duration as a key factor influencing prescriber preferences, with expectations that their regimen will be favored due to its shorter duration compared to competitors.
• Atea confirmed a licensing agreement with Merck for ruzasvir, which includes milestone payments and royalties upon successful commercialization.

Overall, Atea Pharmaceuticals is positioned for significant developments in 2026, with a focus on advancing its HCV and HEV programs while navigating a competitive landscape.